EXHIBIT 26

```
1
            IN THE UNITED STATES DISTRICT COURT
            FOR THE NORTHERN DISTRICT OF OHIO
 2.
                     EASTERN DIVISION
 3
 4
    IN RE: NATIONAL PRESCRIPTION : MDL NO. 2804
    OPIATE LITIGATION
 5
    THIS DOCUMENT RELATES TO: : Case No. 17-md-2804
 6
                                  : Judge Dan A. Polster
 7
    Track Eight
 8
 9
                 Thursday, August 3, 2023
10
                    HIGHLY CONFIDENTIAL
         SUBJECT TO FURTHER CONFIDENTIALITY REVIEW
11
12
13
               Remote deposition of SHANNON L. BRICE,
14
    commencing at 10:11 a.m., on the above date, before
15
    Carol A. Kirk, Registered Merit Reporter, Certified
16
    Shorthand Reporter, and Notary Public.
17
18
19
20
21
22
                GOLKOW LITIGATION SERVICES
            877.370.3377 ph | 917.591.5672 fax
23
                      deps@golkow.com
2.4
```

```
1
           REMOTE APPEARANCES
2
3
    On behalf of the Plaintiffs:
 4
           SIMMONS HANLY CONROY
                LAURA S. FITZPATRICK, ESQUIRE
5
                  lfitzpatrick@simmonsfirm.com
           112 Madison Avenue, 7th Floor
           New York, New York 10016
6
           212-257-8482
7
           SIMMONS HANLY CONROY
8
                SARAH BURNS, ESQUIRE
                 sburns@simmonsfirm.com
 9
           One Court Street
           Alton, Illinois 62002
10
           618-693-3104
11
12
    On behalf of Defendant Publix Super Markets, Inc.:
13
           BARNES & THORNBURG LLP
14
                MONICA BROWNEWELL SMITH, ESQUIRE
                mbrownewell@btlaw.com
15
           11 South Meridian Street
           Indianapolis, Indiana 46204
16
           317-231-7205
17
18
19
20
21
22
23
24
```

Highly Confidential - Subject to Further Confidentiality Review Case: 1:17-md-02804-DAP Doc #: 5437-30 Filed: 05/13/24 4 of 18. PageID #: 636791

```
1
           REMOTE APPEARANCES
2
3
    On behalf of Defendant The Kroger Company:
4
           SWIFT, CURRIE, McGHEE & HIERS, LLP
           BY: NOAH CALDWELL, ESQUIRE
5
                 noah.caldwell@swiftcurrie.crom
           1420 Peachtree Street, NE, Suite 800
6
           Atlanta, Georgia 30309
           404-874-8800
7
8
 9
10
    ALSO PRESENT:
11
           Brannen Wilson, Publix
           Bill Hammond, Publix
12
           Jonathan Jaffe
           Amanda Unterreiner, Motley Rice
13
           Gina Veldman, Trial Tech
14
15
16
17
18
19
20
21
22
23
24
```

1	INDEX TO EXAMINATION	
2	WITNESS	PAGE
3	SHANNON L. BRICE	
4	CROSS-EXAMINATION BY MS. FITZPATRICK	8
5	REDIRECT EXAMINATION BY MS. SMITH RECROSS-EXAMINATION BY MS. FITZPATRICK	364 365
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		

1		INDEX TO EXHIBITS	
2	BRICE	DESCRIPTION	PAGE
3	Exhibit 1	Personnel file for Shannon Brice, Bates-stamped P-PUB-785A	86
4		and 786, 225 pages	
5	Exhibit 2	Regulations and Associated Publix Policies," Bates-stamped PUBLIX-MDLT8-00003532 through	229
6			
		3571	
8	Exhibit 3	Document titled "Chapter 8: Regulations and Associated Publix Policies," Bates-stamped	229
10		PUBLIX-MDLT8-000027405 through 27449	
11	Exhibit 4	E-mail to M. Chavez from D. Bland, dated May 23, 2019,	247
12		with attachment, Bates-stamped PUBLIX-MDLT8-00114908 through	
13		114910	
14	Exhibit 5	E-mail to C. Madill from T. Seymour, dated 1/11/2021,	261
15		with attachment, Bates-stamped PUBLIX-MDLT8-00082132 through 82133	
17	Evhihit 6	E-mail to Pharmacy 0496 from	272
18	Exhibit 6	L. Jacobson, dated 7/22/2019, with attachment, Bates-stamped	212
19		PUBLIX-MDLT8-00076593 through 76596	
20	Exhibit 7	E-mail string ending with an e-mail to M. Chavez from	293
21		Pharmacy 0496, Bates-stamped PUBLIX-MDLT8-00077873 through	
22		77877	
23			
24			

1		INDEX TO EXHIBITS (CONT'D)	
2	BRICE	DESCRIPTION	PAGE
3	Exhibit 8	E-mail string ending with an e-mail to C. Madill from	310
4		M. Chavez, dated 3/14/2019, Bates-stamped PUBLIX-MDLT8-	
5		00074321	
6			
7			
8			
10			
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			

1	
2	PROCEEDINGS
3	
4	THE COURT REPORTER: We are now on
5	the record. My name is Carol Kirk.
6	I am a court reporter for Golkow
7	Litigation Services.
8	Today's date is August 3, 2023,
9	and the time is 10:11 a.m.
10	This remote deposition is being
11	held in the matter of In Re: National
12	Prescription Opiate Litigation, Track 8,
13	for the United States District Court,
14	Northern District of Ohio, Eastern
15	Division. The deponent is Shannon
16	Brice.
17	All parties to this deposition are
18	appearing remotely and have agreed to
19	the witness being sworn in remotely.
20	Due to the nature of remote
21	reporting, please pause briefly before
22	speaking to ensure all parties are heard
23	completely.
24	

```
1
                     SHANNON L. BRICE
2
    being by me first duly sworn, as hereinafter
 3
    certified, deposes and says as follows:
 4
                     CROSS-EXAMINATION
5
    BY MS. FITZPATRICK:
 6
                   Good morning, Ms. Brice.
             0.
7
             Α.
                   Hi.
8
                   Good morning. My name is
             Q.
 9
    Laura Fitzpatrick, and I'm here today on behalf
10
    of Cobb County, among other plaintiffs, in the
11
    National Prescription Opiate Litigation.
12
                   You and I met just now this
13
    morning for the first time via Zoom; is that
14
    correct?
15
             Α.
                   Yes.
16
             Q.
                   And I know it's kind of a funny
17
    thing.
            It's a new world that we live in where
18
    we're doing these depositions via Zoom. But
19
    when I say we met, I only mean to imply that you
20
    and I, we've never met in person, but we met for
21
    the first time this morning via this
22
    videoconferencing app, correct?
23
             Α.
                   Correct.
24
             Q.
                   Okay. Thank you.
```

Highly Confidential - Subject to Further Confidentiality Review Case: 1:17-md-02804-DAP Doc #: 5437-30 Filed: 05/13/24 10 of 18. PageID #: 636797

```
1
                   Now, Ms. Brice, if you would,
2
    please, for the record state your full name.
 3
                   Shannon Leigh Brice.
             Α.
 4
                   How do you spell Leigh, if you
             Q.
5
    don't mind me asking?
 6
             Α.
                   L-e-i-q-h.
7
                   I'm Laura Leigh. That's why
             Q.
8
    I asked, and I'm spelled the same way. So we
9
    already have something in common.
10
                   Now, Ms. Brice -- and is this how
11
    you'd like for me to refer to you today, is
12
    Ms. Brice? There's no other name?
13
             Α.
                   No. That's fine.
14
             Q.
                   Okay. Thank you.
15
                   Now, Ms. Brice, where do you
16
    currently live?
17
             Α.
                   109 North Springs Way, Acworth,
18
    Georgia.
19
             Q.
                   Have you always lived in Acworth?
20
             Α.
                   No.
21
                   And is Acworth in Cobb County,
             0.
22
    Ms. Brice?
23
             Α.
                   Not where we are.
24
             Q.
                   Okay. What county are you in?
```

Highly Confidential - Subject to Further Confidentiality Review Case: 1:17-md-02804-DAP Doc #: 5437-30 Filed: 05/13/24 11 of 18. PageID #: 636798

```
1
    I'm getting at.
 2
                   MS. SMITH: Object to form.
 3
             Α.
                   The -- if it was a controlled
 4
    substance, that would depend on -- I would
 5
    not -- I would not myself then go and try to
 6
    order it from another warehouse. That is all
7
    handled corporately.
8
             Q.
                   Got it.
 9
                   Okay. That was one of the -- that
10
    was going to be my next question, if that was
11
    something the pharmacist did or if that was
12
    something handled by corporate in terms of --
13
             Α.
                   That's my understanding. Yes.
14
                   Okay. And roughly what was the
             Q.
15
    turnaround time, in your experience, when an
16
    order was flagged or held up for some reason,
17
    the time between when that happened until when
18
    you were actually able to get the medication
19
    that you were trying to order, whether it be
20
    through Publix who, you know, replaced the order
21
    for you with its own warehouse or Publix placing
22
    the order with an outside wholesaler, wholesale
23
    distributor?
24
             Α.
                   We would receive an e-mail when
```

Highly Confidential - Subject to Further Confidentiality Review Case: 1:17-md-02804-DAP Doc #: 5437-30 Filed: 05/13/24 12 of 18. PageID #: 636799

```
1 the order then got approved. It was usually
2 within 24 to 48 hours. I don't think it was
3 longer than that.
4 Q. And in your experience, were most
5 of those orders that got flagged at some point
```

7 A. Yes.

approved?

6

- Q. Thank you.
- 9 I may come back to this in a bit.
- 10 But I want to -- well, let me ask you this:
- 11 Would you have any conversations with
- 12 Ms. Jacobson or Mr. Chavez about this process
- 13 generally --
- MS. SMITH: Object to form.
- 15 Q. -- the approval process?
- 16 A. I have not, but if I had a
- 17 question about anything, then, yes, then I would
- 18 get with my pharmacy supervisor, and they would,
- 19 you know, guide me or answer my question about
- 20 it.
- Q. Okay. Thank you.
- Now, we started on this topic, and
- 23 we got a little off the road. We had a little
- 24 detour for a bit.

Highly Confidential - Subject to Further Confidentiality Review Case: 1:17-md-02804-DAP Doc #: 5437-30 Filed: 05/13/24 13 of 18. PageID #: 636800

- 1 matter in the way that you recalled the subject
- 2 matter of the two separate e-mails we just
- 3 discussed, right?
- 4 A. That's correct.
- 5 Q. Okay. Now, what about --
- 6 I specifically asked about e-mails. What about
- 7 documents generally? So any other types of
- 8 documents other than e-mails that you reviewed
- 9 with the lawyers for Publix?
- MS. SMITH: Same objection.
- 11 A. I think there may have been a page
- 12 out of an R&P guide.
- 13 Q. And an R&P -- I'm so sorry.
- 14 I didn't mean to interrupt. Please go ahead.
- 15 A. But I don't remember other than
- 16 that. I don't remember.
- 17 Q. And is an R&P quide different from
- 18 the reference and procedure guide, or is that --
- 19 A. That is.
- 20 Q. Do you recall what chapter that
- 21 was from?
- 22 A. No.
- 23 Q. Do you recall the subject of the
- 24 page from the Publix reference and procedure

- 1 guide you reviewed?
- 2 A. It was a list of items to consider
- 3 when deciding whether or not a prescription
- 4 presented to you was a legitimate prescription
- 5 for a controlled substance.
- 6 Q. And had you seen that part of the
- 7 manual before?
- 8 A. No.
- 9 Q. So that was the first time that
- 10 you saw that list of -- sorry. I lost my
- 11 realtime here, but I think I'm going to get it
- 12 back.
- Was that the first time that you
- 14 had seen that list of items to consider when
- deciding whether or not a prescription presented
- 16 to you was a legitimate prescription for a
- 17 controlled substance?
- MS. SMITH: Object to form.
- 19 A. That was the first time I'd seen
- it presented from within the R&P guide, yes.
- Q. Yes, ma'am. And you have been --
- 22 and we're going to get to your -- I'm skipping
- 23 ahead a little bit to your background, but
- you've been a Publix pharmacist since 1998; is

- 1 about some patients just because I don't know
- 2 them very well.
- 3 Q. Right. And unless it's documented
- 4 in the computer system, another Publix
- 5 pharmacist at another store or even at that
- 6 store wouldn't have the benefit of those
- 7 conversations, right?
- MS. SMITH: Object to form.
- 9 A. Not conversations between me and
- 10 my partner. No.
- 11 Q. About suspicious patients or
- 12 suspicious prescribers, right?
- 13 A. Correct, if it was something that
- 14 the two of us were just discussing about a
- 15 particular prescription.
- 16 O. And Publix does not have a
- 17 prescriber monitoring program, does it?
- MS. SMITH: Object to form.
- 19 A. Not that I'm aware of. No.
- Q. Okay. And there's no uniform way
- 21 for -- well, strike that.
- 22 Publix does not have a central do
- 23 not fill list, does it?
- 24 A. No.

Highly Confidential - Subject to Further Confidentiality Review Case: 1:17-md-02804-DAP Doc #: 5437-30 Filed: 05/13/24 16 of 18. PageID #: 636803

```
1
             Q.
                   Okay. And Publix does not have a
    centralized method by which Publix tracks or
 3
    notifies pharmacists of problematic prescribers,
 4
    right?
 5
             Α.
                   Not that I'm aware of. No.
 6
             Ο.
                   And Publix does not -- although
7
    you document due diligence and should be
8
    commended for that, Publix does not have a
 9
    requirement that pharmacists document due
10
    diligence done in the resolution of red flags,
11
    does it?
12
                   MS. SMITH: Object to form.
13
                   I'm not aware of one if there is.
            Α.
14
             Q.
                   Okay. Have you ever heard,
15
    Ms. Brice, of a -- well, let me back up.
                   Has Ms. Bunch ever specifically
16
17
    mentioned to you the name of any physicians that
18
    she is concerned of writing inappropriate
19
    controlled substance prescriptions?
20
             Α.
                   Not that I can recall.
21
             Ο.
                   Okay. Does the name Dr. Gigi
22
    Bell-Wade ring a bell to you?
23
             Α.
                   I know that we've received -- I've
24
    seen that doctor's prescriptions, yes.
```

Highly Confidential - Subject to Further Confidentiality Review Case: 1:17-md-02804-DAP Doc #: 5437-30 Filed: 05/13/24 17 of 18. PageID #: 636804

```
1
             Q.
                   Have you filled controlled
    substances prescriptions written by that
 3
    physician?
 4
             Α.
                   I believe so, yes.
 5
             Q.
                   Okay. And has anyone at Publix
    ever talked to you about any concerns regarding
 6
7
    Dr. Wade's prescriptions?
8
                   Not that I can recall.
             Α.
 9
                   And Ms. Bunch, who was in your own
             Q.
    store and who you work with, has not talked to
10
11
    you about concerns related to Dr. Wade?
12
             Α.
                   No, not that I can remember.
13
                   Okay. I want to briefly touch on
             Q.
14
    a couple things.
15
                   I know we talked about some of
16
    your -- you're a salaried employee, but you
17
    also -- pharmacists at Publix can also receive
18
    bonuses; is that right?
19
             Α.
                   Yes.
20
                   And those bonuses are based in
             Ο.
21
    part on script volume?
22
                   MS. SMITH: Object to form.
23
             Α.
                   No.
24
                   You're not aware that Publix's
             Q.
```

Highly Confidential - Subject to Further Confidentiality Review Case: 1:17-md-02804-DAP Doc #: 5437-30 Filed: 05/13/24 18 of 18. PageID #: 636805

```
1
    not the case.
 2
             0.
                   I'm not asking you if it's the
 3
    case or not.
                   I'm asking you, as a pharmacist,
 4
    do you think it's an -- do you think it is
 5
    appropriate or inappropriate for any company to
 6
    include controlled substances in script counts,
7
    okay, prescription counts, for the purposes of
8
    pharmacists or pharmacy leader bonus
 9
    calculations?
10
                   MS. SMITH: Objection to form,
11
             calls for speculation.
12
             Α.
                   Then, no, in my opinion, I don't
    think that would be appropriate.
13
14
                   Okay. Do you understand that at
             0.
    Publix -- well, strike that.
15
16
                   Do you agree that it -- have you
17
    received a -- bonuses at Publix, are they
18
    quarterly or yearly?
19
             Α.
                   There are both.
20
                   So do you receive a quarterly --
             Q.
21
    there is an opportunity to earn a quarterly
22
    bonus?
23
                   There is a quarterly bonus, yes.
             Α.
24
             Q.
                   And how does that differ from what
```